As anti-TNF antibody exposed IBD patients generally exhibit markedly diminished response rate to any subsequent biological therapy (vedolizumab or ustekinumab), accurate prediction of response is of high therapeutic importance in this difficult to treat patient group. The gene discussed is TNF; the disease is inflammatory bowel disease.